{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015429","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.630105+00:00","generated_at":"2026-05-30T01:01:15.699995+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Passage Bio Q3 net loss $19.3M; 4 patients enrolled in FTD-GRN Cohort 2; cash to Q2 2026","bullets":["Net loss $19.3M ($0.31/share) vs $27.1M loss a year ago; R&D expenses fell to $8.7M from $15.1M.","Cash and securities $84.8M at Sept 30, 2024; expected runway to end Q2 2026.","Enrolled 4 patients in Cohort 2 of upliFT-D trial; 12-month Cohort 1 and interim Cohort 2 data due 1H25.","Interim Cohort 1 data: PBFT02 raised CSF progranulin for up to 12 months; no serious adverse events with enhanced immunosuppression.","Appointed Tom Kassberg (Ultragenyx CBO) to board of directors and Audit Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015429","json":"https://secwatch.observer/filing/0001558370-24-015429.json","markdown":"https://secwatch.observer/filing/0001558370-24-015429.md","text":"https://secwatch.observer/filing/0001558370-24-015429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024015429/0001558370-24-015429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024015429/pasg-20241113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:01:15.699995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}